BIOLASE Inc. [NASDAQ: BIOL] stock went on a downward path that fall over -1.69% on Wednesday, amounting to a one-week price increase of more than 5.97%. The company report on June 2, 2021 that BIOLASE to Present at the Summer Solstice Best Ideas From the Buy Side Conference on June 2, 2021.
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced that it will be presenting at the Summer Solstice Best Ideas from the Buy Side Conference being held virtually on June 1st – June 4th, 2021. President and CEO John Beaver will be presenting on Wednesday, June 2 at 9:00 am PT and will be hosting virtual one-on-one meetings with institutional investors and analysts throughout the event.
To access a live audio webcast or replay of BIOLASE’s presentation, please click on the following link https://www.webcaster4.com/Webcast/Page/2134/41519 or visit the investor relations section of BIOLASE’s website at www.biolase.com.
Over the last 12 months, BIOL stock rose by 61.19%. The average equity rating for BIOL stock is currently 1.70, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $104.14 million, with 150.56 million shares outstanding and 146.55 million shares in the current float. Compared to the average trading volume of 6.31M shares, BIOL stock reached a trading volume of 2872861 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on BIOLASE Inc. [BIOL]:
The Benchmark Company have made an estimate for BIOLASE Inc. shares, keeping their opinion on the stock as Speculative Buy, with their previous recommendation back on June 19, 2019. While these analysts kept the previous recommendation, Singular Research raised their target price to Buy. The new note on the price target was released on April 25, 2017, representing the official price target for BIOLASE Inc. stock. Previously, the target price had yet another drop from $4 to $2.50, while WallachBeth kept a Hold rating on BIOL stock. On November 12, 2013, analysts decreased their price target for BIOL shares from 3.50 to 2.75.
The Average True Range (ATR) for BIOLASE Inc. is set at 0.05, with the Price to Sales ratio for BIOL stock in the period of the last 12 months amounting to 3.99. The Price to Book ratio for the last quarter was 2.85, with the Price to Cash per share for the same quarter was set at 0.28.
BIOL Stock Performance Analysis:
BIOLASE Inc. [BIOL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.97. With this latest performance, BIOL shares dropped by -2.25% in over the last four-week period, additionally plugging by 137.16% over the last 6 months – not to mention a rise of 61.19% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BIOL stock in for the last two-week period is set at 48.97, with the RSI for the last a single of trading hit 51.12, and the three-weeks RSI is set at 47.65 for BIOLASE Inc. [BIOL]. The present Moving Average for the last 50 days of trading for this stock 0.7644, while it was recorded at 0.7168 for the last single week of trading, and 0.6075 for the last 200 days.
Insight into BIOLASE Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and BIOLASE Inc. [BIOL] shares currently have an operating margin of -81.37 and a Gross Margin at +27.10. BIOLASE Inc.’s Net Margin is presently recorded at -73.88.
Return on Total Capital for BIOL is now -79.85, given the latest momentum, and Return on Invested Capital for the company is -104.10. Return on Equity for this stock declined to -234.22, with Return on Assets sitting at -45.61. When it comes to the capital structure of this company, BIOLASE Inc. [BIOL] has a Total Debt to Total Equity ratio set at 182.14. Additionally, BIOL Total Debt to Total Capital is recorded at 64.56, with Total Debt to Total Assets ending up at 44.52. Long-Term Debt to Equity for the company is recorded at 181.23, with the Long-Term Debt to Total Capital now at 63.48.
Reflecting on the efficiency of the workforce at the company, BIOLASE Inc. [BIOL] managed to generate an average of -$124,659 per employee. Receivables Turnover for the company is 3.85 with a Total Asset Turnover recorded at a value of 0.62.BIOLASE Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.10 and a Current Ratio set at 5.10.
BIOL Stock EPS
With the latest financial reports released by the company, BIOLASE Inc. posted -0.12/share EPS, while the average EPS was predicted by analysts to be reported at -0.17/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 29.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BIOL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BIOLASE Inc. go to 20.00%.
BIOLASE Inc. [BIOL] Insider Position Details
There are presently around $13 million, or 18.10% of BIOL stock, in the hands of institutional investors. The top three institutional holders of BIOL stocks are: VANGUARD GROUP INC with ownership of 7,337,687, which is approximately 469.759% of the company’s market cap and around 0.30% of the total institutional ownership; BLACKROCK INC., holding 3,583,531 shares of the stock with an approximate value of $2.56 million in BIOL stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $1.59 million in BIOL stock with ownership of nearly 1139.98% of the company’s market capitalization.
Positions in BIOLASE Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 30 institutional holders increased their position in BIOLASE Inc. [NASDAQ:BIOL] by around 13,801,978 shares. Additionally, 16 investors decreased positions by around 3,659,029 shares, while 7 investors held positions by with 76,862 shares. The mentioned changes placed institutional holdings at 17,537,869 shares, according to the latest SEC report filing. BIOL stock had 19 new institutional investments in for a total of 1,053,644 shares, while 12 institutional investors sold positions of 3,104,641 shares during the same period.